Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CNS Treatments Highlight US FDA's Busy Pipeline Of Novel Agents For 2018

Executive Summary

Rare disease and infectious disease candidates also are among the most common treatments in agency's review queue.

Advertisement

Related Content

Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic
CDER's 2017 New Drug Class Maintains Steady Innovative Composition With Recent Years
FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week
Keeping Track: A Massive Week Of Agency Approvals
Keeping Track: New MCL Treatment Calquence, Submissions Galore, And A Breakthrough Designation For GSK
Keeping Track: A Burst of CRLs and BTDs, A Busy Week Of Submissions And Another Approval For Soliris
Another Antibiotic Success Story as Tetraphase's Eravacycline Meets Goal
Response Rates Rule In CGRP Inhibitor Migraine Studies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122344

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel